For over two centuries, life expectancy steadily increased, propelled by advances in medicine, sanitation, and public health. However, recent epidemiological data indicate that this upward trajectory has plateaued in developed countries. The implications are profound, suggesting that the conventional approaches to extending lifespan may have reached a limit, emphasizing the necessity to rethink aging not merely as a byproduct of disease but as a fundamental biological process. This study directly addresses this paradigm shift by dissecting aging in its purest form, distinct from pathological conditions.

Dr. Manel Esteller and his team employed cutting-edge multi-omic technologies to paint a detailed molecular picture of this supercentenarian. Crucially, the study’s minimally invasive sampling allowed for extensive biological characterization without compromising the integrity of this precious subject. The integration of various data layers—ranging from chromosomal integrity and gene expression to systemic metabolic and microbial profiles—provides a holistic view that transcends traditional single-omics studies, capturing the coexistence of ageing markers and indicators of sustained physiological resilience.

Surprisingly, their findings reveal a paradoxical duality underlying extreme longevity. While unmistakable hallmarks of aging—such as critically shortened telomeres, a hallmark of chromosomal decay, and a systemic pro-inflammatory immune signature—were clearly present, they coexisted with a set of protective molecular features that may mitigate age-related decline. These include genetic variants associated with neuroprotection and cardioprotection, which presumably confer resilience to neurodegenerative and cardiovascular disorders commonly linked with advanced age.

Another remarkable aspect of Maria Branyas’s biological profile was the demonstration of a biologically younger epigenetic age in contrast to her chronological age. This discovery, quantified using DNA methylation clocks, suggests that specific epigenetic modifications can decouple biological aging from calendar time. This delayed epigenetic aging may be key to her exceptional health span, indicating that biological age could serve as a more accurate biomarker for health and longevity than traditional chronological age.

Moreover, the composition of her gut microbiome was dominated by beneficial bifidobacteria, microorganisms known for their role in modulating immune function and metabolic health. The prominence of such microbial populations aligns with emerging evidence linking microbiome diversity and stability to healthy aging, possibly influencing systemic inflammation and nutrient absorption. Maintaining a balanced microbiota may thus be an essential component in fostering longevity and reducing age-associated morbidity.

The study also highlights the aging of the hematopoietic system – the blood and immune system – which is intimately tied to increased risks of blood cancers like leukemia and myelodysplastic syndromes. The insights drawn from examining Maria Branyas’s blood cellular profile deepen our understanding of hematological aging and suggest potential avenues for preventive strategies or therapeutics targeting immune senescence and oncogenesis in the elderly.

Perhaps most strikingly, this research delineates, for the first time in scientific literature, the biological processes of aging from the development of illness. The subject’s absence of significant pathology allows a rare glimpse into true aging biology, unconfounded by disease effects, providing a blueprint for detecting healthy aging patterns distinct from disease-driven decline. This clarity opens new opportunities for interventions aiming to delay aging effects rather than solely treating associated illnesses.

While the study refrains from attributing causality to specific lifestyle factors, it acknowledges that Mrs. Branyas’s exceptional longevity likely results from a confluence of her dietary habits, rich social network, and avoidance of toxic behaviors such as smoking. These observations are congruent with wider epidemiological data supporting the influence of environment and behavior in modulating aging processes.

Looking forward, the knowledge generated here catalyzes further research into therapeutic strategies for age-associated decline. Epigenetic therapies, already used in oncology to modulate gene expression and combat senescence, emerge as promising candidates to be repurposed for rejuvenation medicine. With aging now recognized as a tractable biological target, such interventions could rekindle the stalled increase in human life expectancy by directly addressing the cellular and molecular underpinnings of aging.

This exceptional multi-disciplinary endeavor is not only a landmark in aging research but also an inspiration for an integrative approach to studying human biology. By leveraging the latest high-throughput technologies and computational methods, the team at the Josep Carreras Institute exemplifies how comprehensive biological data can transform our understanding of the most intricate phenomena—human longevity itself.

Funded by prominent institutions including the Generalitat de Catalunya, the European Community, and the Spanish Ministry of Science, alongside private foundations, this work reflects an international commitment to unravel mechanisms of aging and develop translational pathways to enhance healthspan. Its publication in Cell Reports Medicine ensures broad dissemination within the scientific community, paving the way for future studies that will build upon this pioneering blueprint of extreme human lifespan.

As society grapples with aging populations and increasing healthcare burdens, the findings from Maria Branyas’s biological legacy offer hope that aging, long considered an inexorable decline, may one day be controlled, postponed, or deeply understood. The molecular duality documented here underscores that aging does not equate to inevitable deterioration but may instead be a complex, modifiable process—one that science is just beginning to decode.

Subject of Research: Cells
Article Title: “The multiomics blueprint of the individual with the most extreme lifespan”.
News Publication Date: 24-Sep-2025
Image Credits: Josep Carreras Leukaemia Research Institute
Keywords: Epigenetics, Leukemia, Blood diseases, Aging populations

Standard frontline therapies have improved survival rates; however, patients who experience relapse or are refractory to conventional treatments confront a grim prognosis. A breakthrough in recent years has been the introduction of immunotherapies targeting the CD19 antigen—a surface protein ubiquitously expressed on B-ALL cells. CAR-T (chimeric antigen receptor T-cell) therapies engineered to recognize CD19 have revolutionized treatment paradigms, demonstrating remarkable initial response rates. Yet, clinical outcomes remain unsatisfactory for a substantial subset of patients, with nearly half relapsing primarily due to cancer cells orchestrating immune evasion via downregulation or loss of CD19 expression.

Addressing this mechanism of immune escape, researchers from the Josep Carreras Leukaemia Research Institute and Hospital 12 de Octubre – CNIO undertook pioneering experimental work to develop a dual-targeted CAR-T cell therapy. Led by Dr. Pablo Menéndez, Dr. Clara Bueno, and Dr. Luis Álvarez Vallina, the team designed genetically modified T-cells capable of simultaneously targeting two distinct B-ALL surface antigens: CD19 and CD22. CD22 serves as an alternative, non-overlapping marker consistently present on leukemic blasts, presenting a rational target to complement CD19.

The innovation lies in the sophisticated engineering of the CAR-T cells to combine two complementary strategies within a single therapeutic agent. These CAR-T cells deploy a conventional chimeric antigen receptor construct directed against CD22, facilitating direct cytotoxic engagement of leukemic populations expressing this marker. Simultaneously, these engineered T-cells secrete a bispecific T-cell engager (BiTE) molecule focused on recruiting endogenous T-cells—irrespective of their CAR-T status—towards the CD19 antigen on the tumor cells. This dual mechanism effectively "double-dips" the immune response, enhancing both precision and breadth of leukemic cell targeting.

This approach leverages the unique strengths of both CAR-T technology and bispecific antibody therapy. CAR-T cells offer the advantage of long-lived persistence and sustained cytotoxicity, capable of trafficking throughout the body to eliminate malignancies. In contrast, bispecific antibodies function as bridges that physically tether cytotoxic T-cells to cancer cells, promoting potent immune synapse formation and rapid tumor cell lysis. By integrating BiTE secretion within CAR-T cells, the therapy amplifies immune activation and recruitment, mitigating the risk of tumor cells escaping immune surveillance through antigen loss variants.

Preclinical in vitro investigations revealed that these dual-targeting CAR-T cells markedly improved leukemic control compared to single-antigen targeting counterparts. The bispecific engagement significantly increased the recruitment and activation of bystander T-cells to CD19-expressing leukemia cells, while the direct CD22 CAR-mediated cytotoxicity ensured clearance of leukemic clones that had escaped CD19 targeting. Importantly, this led to prolonged control of leukemic growth and potential reduction in relapse incidence.

Published in the Journal for ImmunoTherapy of Cancer and co-authored by Javier Arroyo Ródenas and Aïda Falgàs, the study marks a pioneering step towards next-generation CAR-T immunotherapies that circumvent antigen escape mechanisms—one of the most formidable barriers to durable remission in relapsed B-ALL. The researchers emphasize that the bifunctional design could redefine treatment paradigms, offering renewed hope for pediatric patients facing limited options after relapse.

The success of this experimental study underscores the importance of multi-antigen targeting within immuno-oncology, particularly in hematological malignancies where antigen heterogeneity and plasticity fuel therapeutic resistance. By harnessing the endogenous immune system’s full cytotoxic potential and imparting long-term surveillance capacity, these "armored" CAR-T cells embody a strategic advance in precision medicine.

Furthermore, the modular construction of these CAR-T cells facilitates adaptability; the BiTE component secreted could theoretically be re-engineered to target alternative tumor-specific antigens or combined with additional immune-stimulatory molecules. This flexibility paves the way for bespoke immunotherapies tailored to diverse malignancies characterized by complex antigenic landscapes.

This research was made possible through funding by several esteemed institutions, including the European Commission’s ERC program, multiple Spanish governmental bodies, regional funds from the Generalitat de Catalunya and Comunidad de Madrid, as well as private entities dedicated to cancer research. Such robust support reflects the growing recognition that innovative immunotherapy solutions are crucial to addressing unmet clinical needs in childhood cancers.

As this CAR-T and bispecific antibody fusion approach progresses towards clinical translation, its implications extend beyond B-ALL. Similar dual-targeting strategies may be exploited for other refractory hematologic cancers and solid tumors notorious for evading mono-targeted immunotherapies. The future of cancer treatment undoubtedly lies in combinatorial immunotherapeutic designs that enhance efficacy while mitigating resistance.

Overall, this study presents a timely, technologically sophisticated immunotherapeutic platform with the potential to transform leukemia care. Its dual targeting mechanism heralds a paradigm shift toward more resilient, lasting remissions for children afflicted with one of the most prevalent and deadly pediatric cancers. Ongoing research and eventual clinical trials will determine its full impact on patient survival and quality of life worldwide.

Subject of Research: Cells

Article Title: CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

News Publication Date: 30-Apr-2025

Web References:
https://doi.org/10.1136/jitc-2024-009048

References:
Arroyo-Ródenas J, Falgàs A, Díez-Alonso L, et al. “CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression”. Journal for ImmunoTherapy of Cancer. 2025;13:e009048. doi:10.1136/jitc-2024-009048

Image Credits: Josep Carreras Leukaemia Research Institute

Keywords: Immunotherapy, Antibody therapy, Cancer immunotherapy, Antibodies, Leukemia